211 related articles for article (PubMed ID: 9322850)
1. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas.
Antinheimo J; Haapasalo H; Haltia M; Tatagiba M; Thomas S; Brandis A; Sainio M; Carpen O; Samii M; Jääskeläinen J
J Neurosurg; 1997 Oct; 87(4):610-4. PubMed ID: 9322850
[TBL] [Abstract][Full Text] [Related]
2. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
3. Allelic losses in neurofibromatosis 2-associated meningiomas.
Lamszus K; Vahldiek F; Mautner VF; Schichor C; Tonn J; Stavrou D; Fillbrandt R; Westphal M; Kluwe L
J Neuropathol Exp Neurol; 2000 Jun; 59(6):504-12. PubMed ID: 10850863
[TBL] [Abstract][Full Text] [Related]
4. A role for the p53 pathway in the pathology of meningiomas with NF2 loss.
Chang Z; Guo CL; Ahronowitz I; Stemmer-Rachamimov AO; MacCollin M; Nunes FP
J Neurooncol; 2009 Feb; 91(3):265-70. PubMed ID: 18974932
[TBL] [Abstract][Full Text] [Related]
5. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
6. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.
Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T
Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas.
Evans JJ; Jeun SS; Lee JH; Harwalkar JA; Shoshan Y; Cowell JK; Golubic M
J Neurosurg; 2001 Jan; 94(1):111-7. PubMed ID: 11147878
[TBL] [Abstract][Full Text] [Related]
9. NF2 mutations in secretory and other rare variants of meningiomas.
Hartmann C; Sieberns J; Gehlhaar C; Simon M; Paulus W; von Deimling A
Brain Pathol; 2006 Jan; 16(1):15-9. PubMed ID: 16612978
[TBL] [Abstract][Full Text] [Related]
10. Clinical course and management of intracranial meningiomas in neurofibromatosis type 2 patients.
Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(6):367-72. PubMed ID: 26652870
[TBL] [Abstract][Full Text] [Related]
11. Radiation-associated meningiomas in children: clinical, pathological, and cytogenetic characteristics with a critical review of the literature.
Elbabaa SK; Gokden M; Crawford JR; Kesari S; Saad AG
J Neurosurg Pediatr; 2012 Oct; 10(4):281-90. PubMed ID: 22900483
[TBL] [Abstract][Full Text] [Related]
12. NF2 status of meningiomas is associated with tumour localization and histology.
Kros J; de Greve K; van Tilborg A; Hop W; Pieterman H; Avezaat C; Lekanne Dit Deprez R; Zwarthoff E
J Pathol; 2001 Jul; 194(3):367-72. PubMed ID: 11439370
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.
Hansson CM; Buckley PG; Grigelioniene G; Piotrowski A; Hellström AR; Mantripragada K; Jarbo C; Mathiesen T; Dumanski JP
BMC Genomics; 2007 Jan; 8():16. PubMed ID: 17222329
[TBL] [Abstract][Full Text] [Related]
15. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients.
Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M
J Neurosurg; 2020 May; 134(5):1377-1385. PubMed ID: 32442973
[TBL] [Abstract][Full Text] [Related]
16. Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas.
Saito K; Kato M; Susaki N; Nagatani T; Nagasaka T; Yoshida J
Clin Neuropathol; 2003; 22(1):30-4. PubMed ID: 12617191
[TBL] [Abstract][Full Text] [Related]
17. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
Abramovich CM; Prayson RA
Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.
Wellenreuther R; Waha A; Vogel Y; Lenartz D; Schramm J; Wiestler OD; von Deimling A
Lab Invest; 1997 Dec; 77(6):601-6. PubMed ID: 9426397
[TBL] [Abstract][Full Text] [Related]
19. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
20. NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study.
Buccoliero AM; Castiglione F; R Degl'Innocenti D; Gheri CF; Garbini F; Taddei A; Ammannati F; Mennonna P; Taddei GL
Neuropathology; 2007 Feb; 27(1):36-42. PubMed ID: 17319281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
